Effect of Xuebijing injection on coagulation function in emergency patients with severe sepsis.

To explore the efficacy of Xuebijing injection in the treatment of emergency patients with severe sepsis and its impact on coagulation function. Methods Seventy-eight patients with severe sepsis were randomly divided into the control group (n = 39) and the Xuebijing group (n = 39) by the random number table method. All patients in both groups were treated with routine anti-sepsis bundle therapy according to the 2016 International Guidelines for the Treatment of Sepsis and Septic Shock. In addition to these routine treatments, the Xuebijing group was treated with a Xuebijing injection, while the control group was given an equal amount of sodium chloride. The platelet count (PLT), coagulation function, thromboelastography (TEG) values, acute physiology and chronic health evaluation II (APACHE II) score, the stay time at the emergency intensive care unit, and the fatality rate within 28 days were compared between these two groups before and after 7 days of treatment. Results After 7 days of treatment, the PLT count in the Xuebijing group increased significantly, and the fibrin/fibrinogen degradation products (FDP) decreased significantly (P < 0.05); the PLT count in the control group continued to decrease (P < 0.01). After 7 days of treatment, FDP and D-Dimer (DD) in the Xuebijing group were lower than those in the control group (P < 0.01), and clot formation time was significantly shortened; α angle, maximum clot strength (MA), and coagulation index (CI) were significantly increased, and all were better than those in the control group (P < 0.05). There was no statistically significant difference in these indicators before and after treatment in the control group (P > 0.05). After 7 days of treatment, APACH II scores in both groups decreased compared to before treatment (P < 0.05), but the performance of the Xuebijing group was better (P < 0.05). The 28-day fatality rate in the Xuebijing group was 17.95%, lower than that in the control group at 23.08%. Conclusions Combined with routine symptomatic treatment, Xuebijing injection could effectively improve the coagulation function of sepsis patients, showing a positive role in the treatment of sepsis patients. [ABSTRACT FROM AUTHOR]